Elan once-daily nifedipine
Executive Summary
Bayer's U.S. subsidiary, Miles Inc., will have exclusive U.S. marketing rights to Elan's sustained-release formulation of the calcium channel blocker under an agreement announced Oct. 17. Bayer was the discoverer of nifedipine and initially licensed U.S. rights to the product to Pfizer, which markets the drug as Procardia. Miles launched its own version of nifedipine as Adalat in 1986. Once approved, the Miles/Elan product will compete with Pfizer's recently launched once-a-day product Procardia XL. Elan filed an NDA in the U.S. for its once-a-day formulation on July 31.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.